Patents by Inventor Gregory Reichard

Gregory Reichard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NK1 ANTAGONISTS
    Publication number: 20170283434
    Abstract: A NK1 antagonist having the formula (I), wherein Ar1 and Ar2 are optionally substituted phenyl or heteroaryl, X1 is an ether, thio or imino linkage, R4 and R5 are not both H or alkyl, and the remaining variables are as defined in the specification, useful for treating a number of disorders, including emesis, depression, anxiety and cough. Pharmaceutical compositions. Methods of treatment and combinations with other agents are also disclosed.
    Type: Application
    Filed: June 23, 2017
    Publication date: October 5, 2017
    Inventors: Sunil Paliwal, Gregory A. Reichard, Cheng Wang, Dong Xiao, Hon-Chung Tsui, Neng-Yang Shih, Juan D. Arredondo, Michelle Laci Wrobleski, Anandan Palani
  • Triazine compounds and compositions thereof and methods for treating malaria and chemoprophylaxis
    Patent number: 9700562
    Abstract: Disclosed herein are triazine compounds and methods of making and using thereof to treat malaria, provide chemoprophylaxis, and/or treat or inhibit infection by one or more Plasmodium spp.
    Type: Grant
    Filed: April 5, 2016
    Date of Patent: July 11, 2017
    Assignee: The United States of America, as represented by the Secretary of the Army, on behalf of the Walter Reed Army Institute of Research
    Inventors: Richard J. Sciotti, Gregory A. Reichard, Kristina M. Pannone, Victor E. Zottig
  • NKantagonists
    Patent number: 9688693
    Abstract: A NK1 antagonist having the formula (I), wherein Ar1 and Ar2 are optionally substituted phenyl or heteroaryl, X1 is an ether, thio or imino linkage, R4 and R5 are not both H or alkyl, and the remaining variables are as defined in the specification, useful for treating a number of disorders, including emesis, depression, anxiety and cough. Pharmaceutical compositions. Methods of treatment and combinations with other agents are also disclosed.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: June 27, 2017
    Assignee: OPKO Health, Inc.
    Inventors: Sunil Paliwal, Gregory A. Reichard, Cheng Wang, Dong Xiao, Hon-Chung Tsui, Neng-Yang Shih, Juan D. Arredondo, Michelle Laci Wrobleski, Anandan Palani
  • Substituted triazines for malaria treatment and chemoprophylaxis
    Patent number: 9334246
    Abstract: Disclosed herein are triazine compounds and methods of making and using thereof to treat malaria, provide chemoprophylaxis, and/or treat or inhibit infection by one or more Plasmodium spp.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: May 10, 2016
    Assignee: The United States of America, as represented by the Secretary of the Army, on behalf of the Walter Reed Army Institute of Research
    Inventors: Richard J. Sciotti, Gregory A. Reichard, Kristina M. Pannone, Victor E. Zottig
  • Substituted Triazines for Malaria Treatment and Chemoprophylaxis
    Publication number: 20150210652
    Abstract: Disclosed herein are triazine compounds and methods of making and using thereof to treat malaria, provide chemoprophylaxis, and/or treat or inhibit infection by one or more Plasmodium spp.
    Type: Application
    Filed: March 13, 2014
    Publication date: July 30, 2015
    Inventors: Richard J. Sciotti, Gregory A. Reichard, Kristina M. Pannone, Victor E. Zottig
  • NK1 ANTAGONISTS
    Publication number: 20140336158
    Abstract: A NK1 antagonist having the formula (I), wherein Ar1 and Ar2 are optionally substituted phenyl or heteroaryl, X1 is an ether, thio or imino linkage, R4 and R5 are not both H or alkyl, and the remaining variables are as defined in the specification, useful for treating a number of disorders, including emesis, depression, anxiety and cough. Pharmaceutical compositions. Methods of treatment and combinations with other agents are also disclosed.
    Type: Application
    Filed: July 25, 2014
    Publication date: November 13, 2014
    Inventors: Sunil Paliwal, Gregory A. Reichard, Cheng Wang, Dong Xiao, Hon-Chung Tsui, Neng-Yang Shih, Juan D. Arredondo, Michelle Laci Wrobleski, Anandan Palani
  • NK1 antagonists
    Patent number: 8796299
    Abstract: A NK1 antagonist having the formula (I), wherein Ar1 and Ar2 are optionally substituted phenyl or heteroaryl, X1 is an ether, thio or imino linkage, R4 and R5 are not both H or alkyl, and the remaining variables are as defined in the specification, useful for treating a number of disorders, including emesis, depression, anxiety and cough. Pharmaceutical compositions. Methods of treatment and combinations with other agents are also disclosed.
    Type: Grant
    Filed: September 24, 2012
    Date of Patent: August 5, 2014
    Assignee: OPKO Health, Inc.
    Inventors: Sunil Paliwal, Gregory A. Reichard, Cheng Wang, Dong Xiao, Hon-Chung Tsui, Neng-Yang Shih, Juan D. Arredondo, Michelle Laci Wrobleski, Anandan Palani
  • NKantagonists
    Patent number: 8273895
    Abstract: A NK1 antagonist having the formula (I), wherein Ar1 and Ar2 are optionally substituted phenyl or heteroaryl, X1 is an ether, thio or imino linkage, R4 and R5 are not both H or alkyl, and the remaining variables are as defined in the specification, useful for treating a number of disorders, including emesis, depression, anxiety and cough. Pharmaceutical compositions. Methods of treatment and combinations with other agents are also disclosed.
    Type: Grant
    Filed: December 14, 2010
    Date of Patent: September 25, 2012
    Assignee: Opko Health, Inc.
    Inventors: Sunil Paliwal, Gregory A. Reichard, Cheng Wang, Dong Xiao, Hon-Chung Tsui, Neng-Yang Shih, Juan D. Arredondo, Michelle Laci Wrobleski, Anandan Palani
  • NK1 ANTAGONISTS
    Publication number: 20110098468
    Abstract: A NK1 antagonist having the formula (I), wherein Ar1 and Ar2 are optionally substituted phenyl or heteroaryl, X1 is an ether, thio or imino linkage, R4 and R5 are not both H or alkyl, and the remaining variables are as defined in the specification, useful for treating a number of disorders, including emesis, depression, anxiety and cough. Pharmaceutical compositions. Methods of treatment and combinations with other agents are also disclosed.
    Type: Application
    Filed: December 14, 2010
    Publication date: April 28, 2011
    Applicant: OPKO Health, Inc.
    Inventors: Sunil Paliwal, Gregory A. Reichard, Cheng Wang, Dong Xiao, Hon-Chung Tsui, Neng-Yang Shih, Juan D. Arredondo, Michelle Laci Wrobleski, Anandan Palani
  • NKantagonists
    Patent number: 7902366
    Abstract: A NK1 antagonist having the formula (I), wherein Ar1 and Ar2 are optionally substituted phenyl or heteroaryl, X1 is an ether, thio or imino linkage, R4 and R5 are not both H or alkyl, and the remaining variables are as defined in the specification, useful for treating a number of disorders, including emesis, depression, anxiety and cough. Pharmaceutical compositions. Methods of treatment and combinations with other agents are also disclosed.
    Type: Grant
    Filed: February 21, 2006
    Date of Patent: March 8, 2011
    Assignee: OPKO Health, Inc.
    Inventors: Sunil Paliwal, Gregory A. Reichard, Cheng Wang, Dong Xiao, Hon-Chung Tsui, Neng-Yang Shih, Juan D. Arredondo, Michelle Laci Wrobleski, Anandan Palani
  • Substituted morpholine compounds for the treatment of central nervous system disorders
    Patent number: 7659394
    Abstract: This invention relates to compounds of the formulae I wherein R1-R8, A, X, and Z are defined as in the specification, pharmaceutical compositions containing them and their use in the treatment of central nervous system disorders.
    Type: Grant
    Filed: April 29, 2005
    Date of Patent: February 9, 2010
    Assignee: Pfizer Inc
    Inventors: Nancy S. Barta, Shelly Ann Glase, David L. Gray, Gregory A. Reichard, Lloyd Jerome Simons, Wenijan Xu
  • Fused ring NKantagonists
    Patent number: 7498438
    Abstract: A compound having the general structure shown in Formula 1: or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.
    Type: Grant
    Filed: April 6, 2005
    Date of Patent: March 3, 2009
    Assignee: Schering Corporation
    Inventors: Dong Xiao, Anandan Palani, Cheng Wang, Hon-Chung Tsui, Neng-Yang Shih, Gregory A. Reichard
  • NK1 antagonists
    Patent number: 7122677
    Abstract: A NK1 antagonist having the formula (I), wherein Ar1 and Ar2 are optionally substituted phenyl or heteroaryl, X1 is an ether, thio or imino linkage, R4 and R5 are not both H or alkyl, and the remaining variables are as defined in the in the specification, useful for treating a number of disorders, including emesis, depression, anxiety and cough. Pharmaceuticals compositions. Methods of treatment and combinations with other agents are also disclosed.
    Type: Grant
    Filed: November 12, 2002
    Date of Patent: October 17, 2006
    Assignee: Scherig Corporation
    Inventors: Gregory A. Reichard, Sunil Paliwal, Neng-Yang Shih, Dong Xiao, Hon-Chung Tsui, Sapna Majmundar Shah, Cheng Wang, Michelle Laci Wrobleski
  • NK1 antagonists
    Publication number: 20060199815
    Abstract: A NK1 antagonist having the formula (I), wherein Ar1 and Ar2 are optionally substituted phenyl or heteroaryl, X1 is an ether, thio or imino linkage, R4 and R5 are not both H or alkyl, and the remaining variables are as defined in the specification, useful for treating a number of disorders, including emesis, depression, anxiety and cough. Pharmaceutical compositions. Methods of treatment and combinations with other agents are also disclosed.
    Type: Application
    Filed: February 21, 2006
    Publication date: September 7, 2006
    Inventors: Sunil Paliwal, Gregory Reichard, Cheng Wang, Dong Xiao, Hon-Chung Tsui, Neng-Yang Shih, Juan Arredondo, Michelle Wrobleski, Anandan Palani
  • NKantagonists
    Patent number: 7049320
    Abstract: A NK1 antagonist having the formula (I), wherein Ar1 and Ar2 are optionally substituted phenyl or heteroaryl, X1 is an ether, thio or imino linkage, R4 and R5 are not both H or alkyl, and the remaining variables are as defined in the specification, useful for treating a number of disorders, including emesis, depression, anxiety and cough. Pharmaceutical compositions. Methods of treatment and combinations with other agents are also disclosed.
    Type: Grant
    Filed: December 17, 2002
    Date of Patent: May 23, 2006
    Assignee: Schering Corporation
    Inventors: Sunil Paliwal, Gregory A. Reichard, Cheng Wang, Dong Xiao, Hon-Chung Tsui, Neng-Yang Shih, Juan D. Arredondo, Michelle Laci Wrobleski, Anandan Palani
  • NKantagonists
    Patent number: 7041682
    Abstract: Disclosed are NK1 antagonists having the formula: Also disclosed are methods for treating a number of physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough, using the compounds of formula (I).
    Type: Grant
    Filed: July 2, 2003
    Date of Patent: May 9, 2006
    Assignee: Schering Corporation
    Inventors: Neng-Yang Shih, Steven Wang, Gregory Reichard, Dong Xiao, Cheng Wang
  • NK1 antagonists
    Publication number: 20060094720
    Abstract: Disclosed are NK1 antagonists having the formula: Also disclosed are methods for treating a number of physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough, using the compounds of formula (I).
    Type: Application
    Filed: December 15, 2005
    Publication date: May 4, 2006
    Inventors: Neng-Yang Shih, Steven Wang, Gregory Reichard, Dong Xiao, Cheng Wang
  • Fused ring NK1 antagonists
    Publication number: 20060040975
    Abstract: A compound having the general structure shown in Formula 1: or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.
    Type: Application
    Filed: April 6, 2005
    Publication date: February 23, 2006
    Inventors: Dong Xiao, Anandan Palani, Cheng Wang, Hon-Chung Tsui, Neng-Yang Shih, Gregory Reichard
  • Substituted morpholine compounds for the treatment of central nervous system disorders
    Publication number: 20050245519
    Abstract: This invention relates to compounds of the formulae I wherein R1-R8, A, X, and Z are defined as in the specification, pharmaceutical compositions containing them and their use in the treatment of central nervous system disorders.
    Type: Application
    Filed: April 29, 2005
    Publication date: November 3, 2005
    Inventors: Nancy Barta, Shelly Glase, David Gray, Gregory Reichard, Lloyd Simons, Weijan Xu
  • Halo substituted benzo[b]thiophenes as therapeutic agents
    Publication number: 20050096350
    Abstract: The present invention provides benzo[b]thiophenes of Formula I: wherein R3, R4, R5, R6, R7, Y, and L have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cardiovascular diseases, and cancers. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.
    Type: Application
    Filed: September 7, 2004
    Publication date: May 5, 2005
    Inventors: Michael Connolly, Rocco Gogliotti, Clarence Hurt, Gregory Reichard, Melean Visnick